Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database

Abivax reported positive ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis patients, citing meaningful clinical benefit. The company said the data also strengthens the Phase 3 maintenance safety database, supporting continued development momentum. Overall tone is constructive but specific effect sizes and timing were not provided in the article excerpt.

Analysis

Abivax reported positive ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis patients, citing meaningful clinical benefit. The company said the data also strengthens the Phase 3 maintenance safety database, supporting continued development momentum. Overall tone is constructive but specific effect sizes and timing were not provided in the article excerpt.